Canopy Growth Corporation
NASDAQ:CGCDrug Manufacturers - Specialty & Generic
+$0.01 today
- Market cap
- $212.31M
- Beta
- 0.78
- P/E (TTM)
- -1.8
- EPS (TTM)
- -$0.76
Volume 3.44M
Average 9.97M
CGC Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Canopy Growth CorporationNASDAQ: CGC
Depreciation & Amortization · Q4 FY2025 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q4 FY2025 depreciation & amortization of CA$8.65M fell 24.5% year over year, behind the -7.7% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 29.2% from the prior quarter. Over 3 fiscal years it compounded at -14.0% a year.
Context
- Depreciation & amortization amounted to 10.5% of revenue in FY2025, down 5.5 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -24.5% toward the trailing-twelve-month pace of -7.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
CAD · from the cash flow
- Latest · FY2025
- 50.86M CAD
- Year-over-year change
- +18.0%
- 4-year CAGR
- -17.7%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2026-03-31 | 50.86M | +18.0% |
| FY2024 | 2025-03-31 | 43.12M | -18.9% |
| FY2023 | 2024-03-31 | 53.18M | -33.6% |
| FY2022 | 2023-03-31 | 80.03M | -27.9% |
| FY2021 | 2022-03-31 | 110.94M | — |
Depreciation & Amortization vs competitors
How CGC compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -7.7% is the 5th highest of 9, against a peer median of -9.9%.
- Depreciation & amortization amounts to 12.7% of revenue for CGC, versus a peer median of 6.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $55.54M USD | +5.2% | -0.5% | 23.3% | |
| LTM Mar 2026 | CA$39.79M CAD | -7.7% | -14.0% | 12.7% | |
| LTM Mar 2026 | CA$14.19M CAD | -37.1% | -31.1% | 4.6% | |
| LTM Mar 2026 | $10.43M USD | -42.2% | -11.2% | 33645.2% | |
| LTM Mar 2026 | $9.76M USD | — | -23.7% | 7.2% | |
| LTM Mar 2026 | $6.34M USD | -2.8% | +26.1% | 15.2% | |
| LTM Mar 2026 | $2.79M USD | +41.0% | +9.9% | 0.8% | |
| LTM Mar 2026 | $1.5M USD | -16.9% | +11.8% | — | |
| LTM Mar 2026 | $528K USD | -25.9% | -17.1% | 6.3% | |
BIOABioAge Labs, Inc. | LTM Mar 2026 | $239K USD | +39.8% | +18.2% | 2.3% |
| Peer median (excluding CGC) | — | -9.9% | -0.5% | 6.8% | |
Competitors are the stored peer set for CGC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Mar 2022 | FY2022 Mar 2023 | FY2023 Mar 2024 | FY2024 Mar 2025 | FY2025 Mar 2026 |
|---|---|---|---|---|---|
| Net Income | (258.91M) | (3.08B) | (483.68M) | (604.14M) | (366.64M) |
| Depreciation & Amortization | 110.94M | 80.03M | 53.18M | 43.12M | 50.86M |
| Deferred Income Tax | (8.95M) | (5.73M) | 12.33M | 7.14M | 0 |
| Stock-Based Compensation | 46.69M | 25.32M | 14.18M | (4.21M) | 5.95M |
| Change in Working Capital | 205M | 58.97M | 3.97M | (31.97M) | 20.68M |
| Accounts Receivables | 16.15M | 6.24M | (3.75M) | (4.49M) | 25.69M |
| Inventory | 204.22M | 68.44M | 1.03M | (17.72M) | 3.71M |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (15.37M) | (15.71M) | 6.68M | (9.77M) | (8.72M) |
| Other Non-Cash Items | (640.58M) | 2.36B | 118.08M | 424.3M | 200.17M |
| Operating Cash Flow | (545.81M) | (557.55M) | (281.95M) | (165.75M) | (88.98M) |
| Capital Expenditures | (48.11M) | (10.45M) | (4M) | (11.28M) | (7.44M) |
| Acquisitions (Net) | 103.2M | 14.93M | (955K) | (6.97M) | 0 |
| Purchases of Investments | (379.41M) | (67.15M) | (347K) | (95.34M) | 0 |
| Sales of Investments | 546.01M | 502.59M | 78.55M | 16.43M | 26.5M |
| Other Investing Activities | (2.3M) | (7.88M) | 167.79M | 48.9M | (48.83M) |
| Investing Cash Flow | 230.82M | 433.38M | 241.59M | (47.79M) | (29.77M) |
| Debt Repayment | (50.76M) | 16.98M | (509.78M) | (220.78M) | (24.62M) |
| Common Stock Issued | 2.7M | 1.05M | 81.06M | 385.39M | 374.17M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.53M | (37.72M) | (36.34M) | (15.96M) | 114.02M |
| Financing Cash Flow | (45.53M) | (19.69M) | (465.06M) | 148.66M | 463.57M |
| Effect of Forex Changes | (18.12M) | 44.86M | (1.29M) | 8.39M | 5.05M |
| Net Change in Cash | (378.65M) | (99M) | (506.71M) | (56.49M) | 349.86M |
| Free Cash Flow | (593.92M) | (568M) | (285.95M) | (177.03M) | (96.42M) |
Canopy Growth Corporation
NASDAQ:CGC
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.